ipsapirone

Ipsapirone is a psychoactive drug that acts as a partial agonist at the 5-HT1A serotonin receptor. It belongs to the azapirone class of compounds and was developed as a potential anxiolytic and antidepressant medication. Unlike benzodiazepines, which enhance the effects of GABA, ipsapirone's mechanism of action involves the modulation of serotonin neurotransmission.

Clinical studies have investigated ipsapirone for its effects on anxiety disorders and depression. Its anxiolytic properties are thought to be related to its ability to reduce the firing rate of serotonin neurons. However, its efficacy and tolerability profile has led to its use being less widespread compared to other established treatments for these conditions.

Ipsapirone is orally administered and undergoes metabolism in the liver. Its pharmacokinetic properties have been studied to understand its absorption, distribution, metabolism, and excretion in the body. Side effects can include dizziness, nausea, and headache, though generally considered to be less sedating than traditional anxiolytics. While research has explored its potential, ipsapirone is not a commonly prescribed medication in many regions.